Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

This study is testing the combination of pembrolizumab (immunotherapy) and cabozantinib (a targeted therapy that blocks tumor growth and blood vessel formation) in patients with advanced sarcomas — rare cancers of bone and soft tissue — that have come back or stopped responding to standard treatment. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with one of the following: undifferentiated pleomorphic sarcoma, bone osteosarcoma, or Ewing sarcoma - Your cancer is advanced (cannot be surgically removed) or has spread - Your cancer has progressed after standard treatment - You have had no more than three prior lines of treatment for advanced disease - You are in good health (ECOG 0–1) - Tumor tissue from a recent biopsy is available **You may NOT be eligible if:** - You have symptomatic brain metastases - You regularly take corticosteroids (steroid medications) - You have another active cancer diagnosed in the last 2 years - You have received more than three prior lines of systemic therapy for advanced disease Talk to your doctor to see if this trial is right for you.